Pharma Reaserch Prod Co Ltd (214450) — Cash Flow-to-Debt Ratio
Pharma Reaserch Prod Co Ltd (214450) has a Cash Flow-to-Debt Ratio of 0.19x as of December 2025, meaning its operating cash flow of ₩61.53 Billion could theoretically repay 0% of its total liabilities (₩320.01 Billion) in one year. Explore Pharma Reaserch Prod Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Pharma Reaserch Prod Co Ltd Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Pharma Reaserch Prod Co Ltd across 11 annual periods. Also explore how large is Pharma Reaserch Prod Co Ltd's balance sheet for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Pharma Reaserch Prod Co Ltd (2015–2025)
Year-by-year debt coverage analysis for Pharma Reaserch Prod Co Ltd. For market capitalisation and broader financial context, see 214450 stock market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.57x | ₩183.16 Billion | ₩320.01 Billion | ▲ +17.1% |
| 2024 | 0.49x | ₩139.88 Billion | ₩286.26 Billion | ▼ -45.0% |
| 2023 | 0.89x | ₩64.95 Billion | ₩73.09 Billion | ▲ +101.3% |
| 2022 | 0.44x | ₩59.40 Billion | ₩134.55 Billion | ▼ -17.4% |
| 2021 | 0.53x | ₩65.30 Billion | ₩122.20 Billion | ▲ +22.7% |
| 2020 | 0.44x | ₩32.39 Billion | ₩74.41 Billion | ▲ +37.4% |
| 2019 | 0.32x | ₩19.27 Billion | ₩60.85 Billion | ▲ +268.6% |
| 2018 | 0.09x | ₩5.20 Billion | ₩60.56 Billion | ▼ -89.8% |
| 2017 | 0.84x | ₩8.56 Billion | ₩10.18 Billion | ▼ -20.8% |
| 2016 | 1.06x | ₩8.16 Billion | ₩7.69 Billion | ▼ -16.8% |
| 2015 | 1.28x | ₩16.02 Billion | ₩12.56 Billion | — |